Home Cart 0 Sign in  
X

[ CAS No. 2942-59-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 2942-59-8
Chemical Structure| 2942-59-8
Chemical Structure| 2942-59-8
Structure of 2942-59-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 2942-59-8 ]

Related Doc. of [ 2942-59-8 ]

Alternatived Products of [ 2942-59-8 ]

Product Details of [ 2942-59-8 ]

CAS No. :2942-59-8 MDL No. :MFCD00006236
Formula : C6H4ClNO2 Boiling Point : -
Linear Structure Formula :- InChI Key :IBRSSZOHCGUTHI-UHFFFAOYSA-N
M.W : 157.55 Pubchem ID :76258
Synonyms :
AKOS BBS-00004231

Calculated chemistry of [ 2942-59-8 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 36.21
TPSA : 50.19 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.31 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.85
Log Po/w (XLOGP3) : 1.34
Log Po/w (WLOGP) : 1.43
Log Po/w (MLOGP) : -0.51
Log Po/w (SILICOS-IT) : 1.39
Consensus Log Po/w : 0.9

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -2.04
Solubility : 1.44 mg/ml ; 0.00914 mol/l
Class : Soluble
Log S (Ali) : -2.0
Solubility : 1.59 mg/ml ; 0.0101 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.0
Solubility : 1.57 mg/ml ; 0.00998 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.32

Safety of [ 2942-59-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 2942-59-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 2942-59-8 ]
  • Downstream synthetic route of [ 2942-59-8 ]

[ 2942-59-8 ] Synthesis Path-Upstream   1~48

  • 1
  • [ 2942-59-8 ]
  • [ 4433-01-6 ]
YieldReaction ConditionsOperation in experiment
48% With hydrogenchloride; sodium hydroxide In methanol; water Example 4
9.50 g of 2-chloronicotinic acid and 5.30 g of sodium hydroxide are dissolved in a mixture of 40 ml of water and 40 ml of methanol.
Following the addition of 4 g of palladium (5percent by weight on activated carbon) as catalyst, the mixture is stirred for 30 h at 80-85° C. at 0.1 MPa.
The catalyst is then filtered off.
Following acidification to pH 1 using hydrochloric acid, the product, 2,2'-bipyridyl-3,3'-dicarboxylic acid, precipitates out as a white solid.
This gives 3.5 g (48percent yield).
Reference: [1] Patent: US6500956, 2002, B1,
  • 2
  • [ 2942-59-8 ]
  • [ 52200-48-3 ]
Reference: [1] Advanced Synthesis and Catalysis, 2011, vol. 353, # 8, p. 1359 - 1366
  • 3
  • [ 2942-59-8 ]
  • [ 10366-35-5 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2008, vol. 47, # 2, p. 315 - 318
[2] Tetrahedron, 1995, vol. 51, # 48, p. 13177 - 13184
[3] Journal of Organometallic Chemistry, 2012, vol. 713, p. 42 - 50
[4] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 5, p. 1424 - 1427
  • 4
  • [ 2942-59-8 ]
  • [ 38521-46-9 ]
YieldReaction ConditionsOperation in experiment
84% With thiourea In water at 90℃; for 8 h; A suspension of 2-chloronicotinic acid (790 mg, 5 mmol) and thiourea (457 mg, 6 mmol) was suspended in water (15 mL), refluxed at 90°C for 8 h, cooled to room temperature to give a pale yellow suspension. For 8 or so, stirring 10min, adding dilute hydrochloric acid, precipitation of light yellow solid, filtered out drying, the target compound (590mg, 84percent).
Reference: [1] Patent: CN103626693, 2016, B, . Location in patent: Paragraph 0157-0159
[2] Roczniki Chemii, 1932, vol. 12, p. 493,495[3] Chem. Zentralbl., 1932, vol. 103, # II, p. 3400
[4] Journal of the American Chemical Society, 1948, vol. 70, p. 3908,3910
  • 5
  • [ 2942-59-8 ]
  • [ 609-71-2 ]
  • [ 5345-47-1 ]
Reference: [1] Die Pharmazie, 1980, vol. 34, # 5-6, p. 253 - 256
  • 6
  • [ 2942-59-8 ]
  • [ 101012-32-2 ]
Reference: [1] Chinese Chemical Letters, 2011, vol. 22, # 9, p. 1009 - 1012
  • 7
  • [ 67-56-1 ]
  • [ 2942-59-8 ]
  • [ 40134-18-7 ]
YieldReaction ConditionsOperation in experiment
93% for 8 h; Reflux To the 250 ml flask is added in three 15.76g (0.1 µM) 2 - chloro -3 - picolinic acid, 100 ml methanol, under the ice-bath adds by drops 17.85g (0.15 µM) thionyl chloride, stirring and heating to reflux, the stirring reaction 8h. Thin layer chromatography tracking response, the raw materials point disappears, stopping the reaction. Reduced pressure distillation to remove the solvent to obtain light yellow 15.95g, yield 93percent
86%
Stage #1: With oxalyl dichloride In dichloromethane at 20℃; for 3 h;
Stage #2: With triethylamine In dichloromethane for 0.5 h; Cooling with ice
Stage #3: With sodium hydrogencarbonate In water
(1)
Production of methyl 2-chloronicotinate
15.0 g (95.2 mmol) of 2-chloronicotinic acid was dissolved in dichloromethane (150 mL), and 8.37 mL (94.5 mmol) of oxalyl chloride was added thereto.
Six droplets of N,N-dimethylformamide were added to the above mixture, and the resulting mixture was stirred for 3 hours at room temperature. 40.1 mL (286 mmol) of triethylamine and 37 mL (914 mmol) of methanol were sequentially added dropwise to the above reaction mixture under ice cooling, and the resulting mixture was stirred for 30 minutes under ice cooling.
The solvent was distilled off under reduced pressure from the reaction mixture, and then an aqueous solution of sodium hydrogen carbonate was added to the residue.
The resulting mixture was extracted with diethyl ether.
The organic phase was washed with water, dried, and concentrated, and the residue was purified by column chromatography (ethyl acetate:n-hexane=1:4).
13.9 g of the title compound was obtained as a pale yellow liquid (yield: 86percent).
1H-NMR data (CDCl3/TMS δ (ppm)):
3.97 (3H, s), 7.33 (1H, dd), 8.17 (1H, dd), 8.53 (1H, dd)
67% at 150℃; for 0.333333 h; Microwave irradiation Example 136; Preparation of 2-chloro-pyridine-3-carboxylic acid methyl esterA mixture a 2-chloro nicotinic acid (2.0 g, 12.7 mmol), trimethyl ortho formate (8 ml) and methanol (10 drops) was heated to 15O0C for 20 minutes in a microwave. The solution was allowed to cool to room temperature, diluted with ethyl acetate and washed with aqueous sodium hydroxide (2M). The organic extract was dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: 0-40percent ethyl acetate in hexane) to give 2-chloro-pyridine-3-carboxylic acid methyl ester as a colourless oil (1.453 g, 67percent yield).1H-NMR (400 MHz, CDCl3): 3.97 (3H5 s, Me), 7.33 (IH, m, CH), 8.19 (IH, m, CH), 8.52 (IH, m, CH) ppm.
Reference: [1] Patent: CN105061399, 2017, B, . Location in patent: Paragraph 0010; 0029; 0030
[2] Patent: US2011/287937, 2011, A1, . Location in patent: Page/Page column 72-73
[3] Patent: WO2007/71900, 2007, A1, . Location in patent: Page/Page column 94
[4] Yakugaku Zasshi, 1952, vol. 72, p. 1336,1338[5] Chem.Abstr., 1953, p. 4336
[6] Patent: WO2003/76408, 2003, A2, . Location in patent: Page/Page column 40-41
[7] Patent: WO2004/72038, 2004, A1, . Location in patent: Page 39
[8] Patent: WO2005/9966, 2005, A1, . Location in patent: Page/Page column 76
  • 8
  • [ 2942-59-8 ]
  • [ 40134-18-7 ]
YieldReaction ConditionsOperation in experiment
98% With thionyl chloride; triethylamine In methanol; toluene EXAMPLE 3:
Preparation of methyl 2-chloronicotinate (6)
81,9 g of thionyl chloride are slowly added to 20 g of 2-chloronicotinic acid (1), under stirring, and the suspension is stirred for 5 minutes.
The mixture is heated to reflux for 60 minutes till obtaining a clear solution which is evaporated under vacuum.
The residue is taken up into 200 ml of anhydrous toluene and concentrated under vacuum to 100 ml.
The obtained solution is slowly dropped into a solution of 9 g of methanol and 14,6 g of triethylamine in 100 ml of anhydrous toluene, keeping temperature at about 20°C, under stirring.
The mixture is left to stand for 5 hours, then cooled to +5°C and the precipitated triethylamine hydrochloride is filtered and washed with 20 ml of toluene.
The organic phase is washed with 50 ml of 5percent p/v aqueous sodium hydrogen carbonate, then with 2 x 200 ml of water, dried over sodium sulfate, filtered and concentrated under vacuum to remove the solvent.
21,35 g of methyl 2-chloronicotinate are obtained in form of a slightly yellow oil, having b.p. 225-230°C, the structure of which is confirmed by the IR and NMR spectra.
Yield about 98percent by mole.
Reference: [1] Patent: EP349902, 1991, A3,
[2] Tetrahedron, 1997, vol. 53, # 47, p. 16061 - 16082
[3] Synthetic Communications, 1996, vol. 26, # 12, p. 2257 - 2272
[4] Journal of Medicinal Chemistry, 1993, vol. 36, # 18, p. 2676 - 2688
[5] Patent: US5767134, 1998, A,
  • 9
  • [ 2942-59-8 ]
  • [ 40134-18-7 ]
YieldReaction ConditionsOperation in experiment
86% With thionyl chloride; triethylamine In 1,4-dioxane; methanol; ethyl acetate EXAMPLE 1
Preparation of 2-chloronicotinic acid methyl ester (18)
To a mixture of 2-chloronicotinic acid (Aldrich, 100.0 g, 0.63 mol) in 1,4-dioxane (500 mL) was added thionyl chloride (70 mL, 0.96 mol).
The suspension was heated under reflux for 22 h with a gas trap to absorb hydrogen chloride gas.
After evaporation of the solvent, the residue was dissolved in methanol (300 mL).
To the solution was added dropwise triethylamine (TEA, 120 mL, 1.26 mol) at 0° C. over 2 h.
The solvents were evaporated and the residue was suspended in ethyl acetate.
The precipitate was removed by filtration.
The filtrate was concentrated to afford the ester 18 (92.3 g, 86percent) as an oil:
Rf(1:5 v/v ethyl acetate-hexane) 0.38.
1H NMR (300 MHz, CDCl3) δ8.53 (dd, 4.8 Hz, 1H), 8.19 (dd, 7.6 Hz, 1H), 7.37 (dd, 7.7 Hz, 1H) and 3.97 (s, 3H).
13C NMR (75 MHz, CDCl3) δ164.5, 151.6, 149.6, 140.0, 126.4, 121.9 and 52.5.
86% With thionyl chloride; triethylamine In 1,4-dioxane; methanol; ethyl acetate Example 1
Preparation of 2-chloronicotinic acid methyl ester (18)
To a mixture of 2-chloronicotinic acid (Aldrich, 100.0 g, 0.63 mol) in 1,4-dioxane (500 mL) was added thionyl chloride (70 mL, 0.96 mol).
The suspension was heated under reflux for 22 h with a gas trap to absorb hydrogen chloride gas.
After evaporation of the solvent, the residue was dissolved in methanol (300 mL).
To the solution was added dropwise triethylamine (TEA, 120 mL, 1.26 mol) at 0° C. over 2 h.
The solvents were evaporated and the residue was suspended in ethyl acetate.
The precipitate was removed by filtration.
The filtrate was concentrated to afford the ester 18 (92.3 g, 86percent) as an oil:
Rf (1:5 v/v ethyl acetate-hexane) 0.38.
1H NMR (300 MHz, CDCl3) δ 88.53 (dd, 4.8 Hz, 1H), 8.19 (dd, 7.6 Hz, 1H), 7.37 (dd, 7.7 Hz, 1H) and 3.97 (s, 3H).
13C NMR (75 MHz, CDCl3) δ 164.5, 151.6, 149.6, 140.0, 126.4, 121.9 and 52.5.
Reference: [1] Patent: US2002/188011, 2002, A1,
[2] Patent: US2002/119955, 2002, A1,
  • 10
  • [ 2942-59-8 ]
  • [ 18107-18-1 ]
  • [ 40134-18-7 ]
YieldReaction ConditionsOperation in experiment
85.42% at 20℃; Intermediate 3. 2-Chloronicotinic acid methyl ester.; To a room temperature solution of2-chloronicotinic acid (5.00 g, 31.7 mmol) in 20percent MeOH/toluene (100 mL) was added TMS diazomethane (trimethylsilyl diazomethane) (2.0M in hexanes, 31.7 mL) dropwise and the reaction was monitored by TLC (thin-layer chromatography) until completion. The reaction was concentrated down under reduced pressure. The residue was purified by silica chromatography using a gradient of hexanes:EtOAc (100:0) to hexanes:EtOAc (80:20) to yield 4.65 g (85.42percent) of Intermediate 3 as a yellow oil. EPO <DP n="36"/>
Reference: [1] Patent: WO2007/31828, 2007, A2, . Location in patent: Page/Page column 34
  • 11
  • [ 186581-53-3 ]
  • [ 2942-59-8 ]
  • [ 40134-18-7 ]
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 3, p. 618 - 624
[2] Journal of Heterocyclic Chemistry, 1997, vol. 34, # 1, p. 27 - 32
[3] Journal of Organic Chemistry, 1997, vol. 62, # 10, p. 3158 - 3175
[4] Journal of the Chemical Society, 1952, p. 2057,2060
  • 12
  • [ 2942-59-8 ]
  • [ 74-88-4 ]
  • [ 40134-18-7 ]
Reference: [1] Patent: US5294610, 1994, A,
[2] Patent: US6197798, 2001, B1,
  • 13
  • [ 2942-59-8 ]
  • [ 77-78-1 ]
  • [ 40134-18-7 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2006, vol. 43, # 5, p. 1311 - 1317
  • 14
  • [ 2942-59-8 ]
  • [ 155058-02-9 ]
  • [ 40134-18-7 ]
Reference: [1] Patent: US5391554, 1995, A,
  • 15
  • [ 186581-53-3 ]
  • [ 36851-80-6 ]
  • [ 2942-59-8 ]
  • [ 40134-18-7 ]
Reference: [1] Patent: US4215123, 1980, A,
  • 16
  • [ 2942-59-8 ]
  • [ 7440-44-0 ]
  • [ 40134-18-7 ]
Reference: [1] Patent: US5965591, 1999, A,
  • 17
  • [ 2942-59-8 ]
  • [ 67367-26-4 ]
Reference: [1] Synthetic Communications, 1996, vol. 26, # 12, p. 2257 - 2272
  • 18
  • [ 67-56-1 ]
  • [ 2942-59-8 ]
  • [ 124-41-4 ]
  • [ 67367-26-4 ]
Reference: [1] Journal of Organic Chemistry, 2002, vol. 67, # 6, p. 1843 - 1847
  • 19
  • [ 2398-81-4 ]
  • [ 10026-13-8 ]
  • [ 10025-87-3 ]
  • [ 2942-59-8 ]
  • [ 10177-29-4 ]
Reference: [1] Chemische Berichte, 1959, vol. 92, p. 2266,2270[2] Arkiv foer Kemi, 1959, vol. 14, p. 419,422
[3] Journal of Organic Chemistry, 1954, vol. 19, p. 1633,1636[4] Org. Synth. Coll., 1963, vol. Vol. IV, p. 166
  • 20
  • [ 2942-59-8 ]
  • [ 36404-88-3 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 5, p. 694 - 707
[2] Journal of Heterocyclic Chemistry, 1995, vol. 32, # 5, p. 1595 - 1597
  • 21
  • [ 2942-59-8 ]
  • [ 32399-12-5 ]
Reference: [1] Bioorganic and medicinal chemistry letters, 2003, vol. 13, # 2, p. 191 - 196
[2] Journal of Medicinal Chemistry, 1990, vol. 33, # 10, p. 2697 - 2706
[3] Patent: US2011/287937, 2011, A1,
  • 22
  • [ 2942-59-8 ]
  • [ 29241-65-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 2, p. 760 - 763
  • 23
  • [ 2942-59-8 ]
  • [ 68359-07-9 ]
Reference: [1] Synthetic Communications, 1989, vol. 19, # 9-10, p. 1505 - 1508
  • 24
  • [ 2942-59-8 ]
  • [ 32399-08-9 ]
Reference: [1] Patent: US2011/287937, 2011, A1,
  • 25
  • [ 2942-59-8 ]
  • [ 16498-81-0 ]
Reference: [1] Patent: US4342771, 1982, A,
  • 26
  • [ 2942-59-8 ]
  • [ 124-41-4 ]
  • [ 16498-81-0 ]
Reference: [1] Synthetic Communications, 1989, vol. 19, # 9-10, p. 1505 - 1508
  • 27
  • [ 2942-59-8 ]
  • [ 54916-65-3 ]
Reference: [1] Synthetic Communications, 1989, vol. 19, # 9-10, p. 1505 - 1508
  • 28
  • [ 2942-59-8 ]
  • [ 100-46-9 ]
  • [ 33522-80-4 ]
YieldReaction ConditionsOperation in experiment
84%
Stage #1: Heating / reflux
Stage #2: With sodium hydroxide In water
Stage #3: With hydrogenchloride In water
Benzylamine (14 mL, 126. 8 mmol) was added to a solution of chloronicotinic acid (10 g, 63.4 mmol) in pyridine and refluxed overnight. The pyridine was distilled and the residue was dissolved in IN NaOH. The solution was diluted with water to adjust the pH to 10 to 11 and washed by dichloromethane. The aqueous phase was neutralized with cold aqueous 10 percent HC1 solution to adjust the pH to 6 to 7. The solids formed were filtered, washed with cold water, and dried in a vacuum oven to yield 12.2 g (84 percent) OF 2-BENZYLAMINO nicotinic acid (1) as white solids. MP: 148 °C ; 1H-NMR (DMSO-d6): d 4.69 (d, J= 3.6 Hz, 2H), 6.61 (dd, J= 4.9, 7.7 Hz, 1H), 7.23 (m, 1H), 7.29 (m, 4H), 8.08 (dd, J = 1.8, 7.0 Hz, 1H), 8. 28 (DD, J = 1.8, 7.0 Hz, 1H), 8.47 (br. s, 1H), 13.10 (s, 1H) ; EIMS: 229 (M+1), 251 (M+23).
Reference: [1] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2108 - 2121
[2] Patent: WO2005/21546, 2005, A1, . Location in patent: Page/Page column 111; 159-160
[3] Tetrahedron Letters, 2003, vol. 44, # 32, p. 6021 - 6023
[4] Tetrahedron, 2005, vol. 61, # 42, p. 10081 - 10092
[5] Tetrahedron Letters, 2009, vol. 50, # 21, p. 2481 - 2483
[6] Journal of Medicinal Chemistry, 1990, vol. 33, # 10, p. 2697 - 2706
[7] Patent: US5854257, 1998, A,
[8] Patent: WO2004/20414, 2004, A1, . Location in patent: Page 97
  • 29
  • [ 2942-59-8 ]
  • [ 87-60-5 ]
  • [ 17737-65-4 ]
Reference: [1] Journal of Medicinal Chemistry, 1990, vol. 33, # 10, p. 2697 - 2706
  • 30
  • [ 2942-59-8 ]
  • [ 98-16-8 ]
  • [ 4394-00-7 ]
Reference: [1] Journal of Medicinal Chemistry, 1990, vol. 33, # 10, p. 2697 - 2706
[2] Medicinal Chemistry Research, 2013, vol. 22, # 5, p. 2411 - 2420
  • 31
  • [ 2942-59-8 ]
  • [ 75-16-1 ]
  • [ 55676-21-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 18, p. 7577 - 7589
[2] Patent: WO2011/79804, 2011, A1, . Location in patent: Page/Page column 24
[3] Patent: US2012/245178, 2012, A1, . Location in patent: Page/Page column 13
  • 32
  • [ 49609-84-9 ]
  • [ 2942-59-8 ]
  • [ 79-37-8 ]
  • [ 594-27-4 ]
  • [ 144-55-8 ]
  • [ 55676-21-6 ]
Reference: [1] Patent: US5688795, 1997, A,
  • 33
  • [ 2942-59-8 ]
  • [ 55676-21-6 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2012, vol. 3, # 9, p. 764 - 768
[2] Patent: US2012/258982, 2012, A1,
[3] European Journal of Medicinal Chemistry, 2012, vol. 57, p. 311 - 322
[4] Bulletin of the Korean Chemical Society, 2013, vol. 34, # 4, p. 1253 - 1256
[5] Bulletin of the Korean Chemical Society, 2015, vol. 36, # 7, p. 1908 - 1911
[6] Patent: WO2006/123145, 2006, A1,
[7] Patent: WO2016/132134, 2016, A1,
[8] Patent: KR101766414, 2017, B1,
  • 34
  • [ 2942-59-8 ]
  • [ 42330-59-6 ]
YieldReaction ConditionsOperation in experiment
68%
Stage #1: With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 50℃; for 1 h;
Stage #2: With sodium hydroxide; water In tetrahydrofuran at 0℃;
(Step 1)
To a suspension of lithium aluminum hydride (8.60 g) in THF (200 mL) was added a solution of 2-chloronicotinic acid (22.4 g) in THF (30 mL) at 0°C, and the mixture was stirred at 50°C for 1 hr.
After the reaction mixture was cooled to 0°C, 1N aqueous sodium hydroxide solution (9 mL) was added.
The precipitate was filtered off, and the filtrate was concentrated.
The residue was purified by silica gel column chromatography (solvent gradient; 10-->25percent ethyl acetate/hexane) to give (2-chloropyridin-3-yl)methanol (14.0 g, 68percent) as a colorless oil.
1H-NMR(CDCl3): δ 2.42-2.75(1H,m), 4.80(2H,d,J=4.8Hz), 7.29(1H,dd,J=7.8,4.8Hz), 7.88-7.93(1H,m), 8.29-8.32(1H,m)
87% With sodium hydroxide; lithium aluminium tetrahydride In tetrahydrofuran; water EXAMPLE 35A
(2-chloro-3-pyridinyl)methanol
A solution of 2-chloronicotinic acid (2.0 g, 12.6 mmol) in THF (15 mL) at 0° C. was treated dropwise with 1M LAH in THF (15 mL, 15.0 mmol), warmed to room temperature, stirred for 5 hours, treated sequentially with water (0.5 mL), 40percent NaOH solution (0.5 mL) and water (1.5 mL), stirred for 2 hours, filtered through a pad of diatomaceous earth (Celite.(R).), and extracted with dichloromethane.
The combined extracts were dried (MgSO4), filtered, and concentrated to provide 1.56 g (87percent) of the desired product of sufficient purity for subsequent use. MS (DCI/NH3) m/z 144 (M+H)+; 1H NMR (CDCl3) δ8.34 (dd, 1H), 7.90 (m, 1H), 7.29 (dd, 1H), 4.80 (s, 2H).
87% With sodium hydroxide; lithium aluminium tetrahydride In tetrahydrofuran; water EXAMPLE 35A
(2-chloro-3-pyridinyl)methanol
A solution of 2-chloronicotinic acid (2.0 g, 12.6 mmol) in THF (15 mL) at 0° C. was treated dropwise with 1M LAH in THF (15 mL, 15.0 mmol), warmed to room temperature, stirred for 5 hours, treated sequentially with water (0.5 mL), 40percent NaOH solution (0.5 mL) and water (1.5 mL), stirred for 2 hours, filtered through a pad of diatomaceous earth (Celite.(R).), and extracted with dichloromethane.
The combined extracts were dried (MgSO4), filtered, and concentrated to provide 1.56 g (87percent) of the desired product of sufficient purity for subsequent use. MS (DCI/NH3) m/z 144 (M+H)+; 1H NMR (CDCl3) δ 8.34 (dd, 1H), 7.90 (m, 1H), 7.29 (dd, 1H), 4.80 (s, 2H).
Reference: [1] Synthesis, 2010, # 20, p. 3439 - 3448
[2] Synthetic Communications, 2008, vol. 38, # 6, p. 889 - 904
[3] Patent: EP2018863, 2009, A1, . Location in patent: Page/Page column 73-74
[4] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 5, p. 694 - 707
[5] Journal of Heterocyclic Chemistry, 1995, vol. 32, # 5, p. 1595 - 1597
[6] Patent: US2003/87940, 2003, A1,
[7] Patent: US2002/115640, 2002, A1,
[8] Patent: US5739326, 1998, A,
[9] Chinese Chemical Letters, 2011, vol. 22, # 9, p. 1009 - 1012
  • 35
  • [ 2942-59-8 ]
  • [ 78607-36-0 ]
Reference: [1] Advanced Synthesis and Catalysis, 2011, vol. 353, # 8, p. 1359 - 1366
  • 36
  • [ 2942-59-8 ]
  • [ 77152-08-0 ]
  • [ 131747-43-8 ]
Reference: [1] Journal of Organic Chemistry, 2013, vol. 78, # 22, p. 11126 - 11146
  • 37
  • [ 2942-59-8 ]
  • [ 133627-47-1 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1993, vol. 30, # 3, p. 771 - 779
  • 38
  • [ 2942-59-8 ]
  • [ 112197-16-7 ]
Reference: [1] Synthetic Communications, 1996, vol. 26, # 12, p. 2257 - 2272
  • 39
  • [ 2942-59-8 ]
  • [ 116834-96-9 ]
Reference: [1] Patent: WO2011/79804, 2011, A1,
[2] Patent: US2012/245178, 2012, A1,
[3] European Journal of Medicinal Chemistry, 2012, vol. 57, p. 311 - 322
[4] Journal of Medicinal Chemistry, 2014, vol. 57, # 18, p. 7577 - 7589
  • 40
  • [ 2942-59-8 ]
  • [ 112006-75-4 ]
Reference: [1] Patent: CN106749183, 2017, A,
  • 41
  • [ 2942-59-8 ]
  • [ 338990-31-1 ]
Reference: [1] Bioorganic and medicinal chemistry letters, 2003, vol. 13, # 2, p. 191 - 196
  • 42
  • [ 2942-59-8 ]
  • [ 155058-02-9 ]
  • [ 40134-18-7 ]
Reference: [1] Patent: US5391554, 1995, A,
  • 43
  • [ 2942-59-8 ]
  • [ 155058-02-9 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2006, vol. 43, # 5, p. 1311 - 1317
  • 44
  • [ 3731-53-1 ]
  • [ 2942-59-8 ]
  • [ 854382-06-2 ]
YieldReaction ConditionsOperation in experiment
89%
Stage #1: at 20℃; for 0.333333 h;
Stage #2: at 110℃; for 2 h;
2 - chloro nicotinic acid (25.3mmol), copper oxide (catalytic amount), potassium carbonate (25.3mmol) is added to the 100 ml round bottom flask, under normal temperature 20min, adding 4 - dimethylamino pyridine (50.6mmol), 110 °C heating 2h. After adding the ethyl acetate to stir to room temperature, filtered, the filter cake washed first with ethyl acetate for 2 times, water (20 ml) dissolved, 4N hydrochloric acid adjusted to pH 5 - 6, standing out, filtered, the filter cake drying, to obtain crude, ethanol heat beating further purification, filtration, forms offwhite solid 5.16g, yield 89percent
Reference: [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 7, p. 2930 - 2943
[2] Patent: CN106565599, 2017, A, . Location in patent: Paragraph 0082-0086
[3] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 21, p. 6003 - 6008
  • 45
  • [ 2942-59-8 ]
  • [ 884049-52-9 ]
Reference: [1] Chinese Chemical Letters, 2011, vol. 22, # 9, p. 1009 - 1012
  • 46
  • [ 2942-59-8 ]
  • [ 896705-16-1 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 11, p. 4950 - 4961
[2] Patent: WO2015/143293, 2015, A1,
  • 47
  • [ 2942-59-8 ]
  • [ 937640-24-9 ]
Reference: [1] Patent: US9334256, 2016, B2,
  • 48
  • [ 2942-59-8 ]
  • [ 337958-60-8 ]
Reference: [1] Patent: WO2011/134971, 2011, A1,
[2] Patent: US2013/40984, 2013, A1,
Recommend Products
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 2942-59-8 ]

Isavuconazonium Sulfate Related Intermediates

Chemical Structure| 32399-12-5

[ 32399-12-5 ]

2-(N-Methylamino)-3-hydroxymethylpyridine

Nevirapine Related Intermediates

Chemical Structure| 21901-18-8

[ 21901-18-8 ]

4-Methyl-3-nitropyridin-2(1H)-one

Chemical Structure| 133627-45-9

[ 133627-45-9 ]

2-Chloro-4-methylpyridin-3-amine

Chemical Structure| 6602-54-6

[ 6602-54-6 ]

2-Chloronicotinonitrile

Chemical Structure| 23056-39-5

[ 23056-39-5 ]

2-Chloro-4-methyl-3-nitropyridine

Chemical Structure| 639807-18-4

[ 639807-18-4 ]

2-(Cyclopropylamino)nicotinic acid

Related Functional Groups of
[ 2942-59-8 ]

Chlorides

Chemical Structure| 66909-30-6

[ 66909-30-6 ]

2-Chloro-5-methylnicotinic acid

Similarity: 0.94

Chemical Structure| 215306-02-8

[ 215306-02-8 ]

2-Chloropyridine-3,4-dicarboxylic acid

Similarity: 0.92

Chemical Structure| 262423-77-8

[ 262423-77-8 ]

2,4-Dichloronicotinc acid

Similarity: 0.86

Chemical Structure| 42330-59-6

[ 42330-59-6 ]

2-Chloro-3-pyridinylmethanol

Similarity: 0.81

Chemical Structure| 62774-90-7

[ 62774-90-7 ]

2,6-Dichloro-4-methylnicotinic acid

Similarity: 0.81

Carboxylic Acids

Chemical Structure| 66909-30-6

[ 66909-30-6 ]

2-Chloro-5-methylnicotinic acid

Similarity: 0.94

Chemical Structure| 215306-02-8

[ 215306-02-8 ]

2-Chloropyridine-3,4-dicarboxylic acid

Similarity: 0.92

Chemical Structure| 262423-77-8

[ 262423-77-8 ]

2,4-Dichloronicotinc acid

Similarity: 0.86

Chemical Structure| 62774-90-7

[ 62774-90-7 ]

2,6-Dichloro-4-methylnicotinic acid

Similarity: 0.81

Chemical Structure| 505084-59-3

[ 505084-59-3 ]

2-Chloro-5-(trifluoromethyl)nicotinic acid

Similarity: 0.80

Related Parent Nucleus of
[ 2942-59-8 ]

Pyridines

Chemical Structure| 66909-30-6

[ 66909-30-6 ]

2-Chloro-5-methylnicotinic acid

Similarity: 0.94

Chemical Structure| 215306-02-8

[ 215306-02-8 ]

2-Chloropyridine-3,4-dicarboxylic acid

Similarity: 0.92

Chemical Structure| 262423-77-8

[ 262423-77-8 ]

2,4-Dichloronicotinc acid

Similarity: 0.86

Chemical Structure| 42330-59-6

[ 42330-59-6 ]

2-Chloro-3-pyridinylmethanol

Similarity: 0.81

Chemical Structure| 62774-90-7

[ 62774-90-7 ]

2,6-Dichloro-4-methylnicotinic acid

Similarity: 0.81